Eyepoint Q2 results and update

 –Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration remains on track to report topline data in December 2023 –

–Phase 2 PAVIA clinical trial evaluating EYP-1901 innon-proliferative diabetic retinopathy remains on track with topline data anticipated in 2Q 2024 –

–Jay S. Duker, M.D. promoted to President and Chief Executive Officer –

–YUTIQ^® franchise sold for $82.5 million cash plus future royalties; all outstanding bank debt retired and cash runway extended into 2025 –

–Management to host a conference call and webcast today at 8:30 a.m. ET –

EyePoint will host a conference call today, at 8:30 a.m. ET to discuss the results for the second quarter ended June 30, 2023 and recent corporate developments. To access the live conference call, please register at https://register.vevent.com/register/BI1f9c401d832f439690f47dc2454e01d6. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.

https://www.biospace.com/article/releases/eyepoint-pharmaceuticals-reports-second-quarter-2023-financial-results-and-highlights-recent-corporate-developments/